Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a quickly progressing disease in which too many abnormal white blood cells are found in the bone marrow (the soft, spongy center of long bones). Acute lymphoblastic leukemia accounts for about 75 to 80 percent of childhood leukemias, and 85 percent of newly diagnosed patients go on to become event-free survivors. In some cases, children who are treated for ALL and achieve an initial complete remission will have the disease return; this is known as relapsed acute lymphoblastic leukemia.
Children and teens with acute lymphoblastic leukemia are treated at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center through the Leukemia Treatment Program. Continue reading to learn more about ALL or visit the Leukemia Treatment Program page to learn about our expertise and treatment options for this condition.
is a blood cancer. It develops in the bone marrow – the soft, spongy center of
the long bones that produces the three major blood cells: white blood cells (to fight
infection); red blood cells (to carry oxygen); and platelets (to help blood clot and
Because leukemia is a cancer of the bone marrow, the initial symptoms often are related to abnormal bone marrow function. Bone marrow is responsible for producing the body's blood cells, including the red blood cells, white blood cells, and platelets. While your child may experience symptoms differently, some of the most common ALL symptoms include:
ALL can cause a variety of symptoms in children based on their age and their disease type. Keep in mind that the symptoms of ALL may resemble other more common conditions or medical problems. Always consult your child's physician for a diagnosis.
Your child’s physician may order a number of different tests to determine whether your child has ALL and what type of ALL your child has. In addition to a physical examination and history, some of these may include:
After we complete all necessary tests, our experts meet to review and discuss what they have learned about your child's condition. Then, we will meet with you and your family to discuss the results and outline the best treatment options for your child's leukemia.
Your child’s physician will determine a specific course of treatment for childhood leukemia based on several factors, including:
Treatment for ALL is a long-term process. Chemotherapy and other treatment for the disease may take two years or more to complete.
There are a number of treatments that your child’s physician may recommend. Some of them help to treat the leukemia, while others are intended to address complications of the disease or side effects of the treatment. Treatment usually begins by addressing your child’s symptoms, such as anemia, bruising, and/or fever. In addition, treatment may include the following (alone or in combination):
Chemotherapy is a drug treatment that interferes with the cancer cell's ability to grow or reproduce. For some types of cancer, chemotherapy is used alone, while in others it is used in conjunction with other therapy, such as radiation or surgery. Chemotherapy is the standard first treatment for acute lymphoblastic leukemia (ALL).
How is chemotherapy given to children?
Your child may receive chemotherapy:
Does chemotherapy cause side effects in children?
While chemotherapy can be quite effective in treating certain cancers, the medications don’t distinguish healthy cells from cancer cells. As a result, there can be side effects during treatment. Your child’s care team will work to manage or prevent these side effects whenever possible.
What other treatments are used?
Radiation therapy uses high-energy rays (radiation) from a specialized machine to damage or kill cancer cells and shrink tumors. Radiation is usually only given if your child is at a high risk of relapse occurring in the brain or central nervous system.
Stem cell transplant
A stem cell (or bone marrow) transplant is a treatment that is rarely used to treat ALL except for:
Stem cells are a specific type of cell from which all blood cells develop. They can develop into red blood cells to carry oxygen, white blood cells to fight disease and infection and platelets to aid in blood clotting. Stem cells are found primarily in bone marrow, but some also circulate in the blood stream.
In acute lymphoblastic leukemia, the cells for a stem cell transplant come from donors (other people). These donated cells are used to replace your child’s stem cells after particularly intense treatment with chemotherapy and/or radiation.
KYMRIAH CAR T-Cell Therapy
(chimeric antigen receptor) T-cell therapy is a promising new treatment for relapsed or refractory B-cell ALL. It works by modifying the body's T-cells, a type of immune system cell that hunts and destroys abnormal cells, such as cancer cells.
We may give your child other medications to prevent or treat damage to other systems of his body caused by treatment or its side effects. Your child also may be given antibiotics to prevent or treat infections.
What is sanctuary therapy?
In children with ALL, leukemia cells travel everywhere in the body, including into the brain and spinal fluid. Not all chemotherapy drugs that are given by mouth, by vein, or in the muscle can get into the brain effectively to treat any leukemia that is “hiding” there.
However, it is important to treat the leukemia cells hiding in the brain and spinal fluid to prevent the leukemia from coming back. To treat the leukemia hiding in the brain and spinal fluid, your child will receive:
Your child may also receive:
In general, stages in the treatment of acute lymphoblastic leukemia (ALL) include:
Phase 1: Remission induction
Remission induction is the first stage of ALL treatment. It consists of chemotherapy given over a four-week period to clear the marrow of visible leukemia cells. The goal of this phase is to achieve complete remission, which means leukemia cells are no longer visible under a microscope when examining either the bone marrow or blood.
The induction phase usually lasts approximately one month. Most children are in complete remission at the end of the month of treatment. If your child is not in remission after the first month (that is, leukemia cells can still be seen in the marrow under a microscope), another induction phase will be started using different chemotherapy drugs.
Even after remission is achieved, leukemia cells are still present in the body, which is why further therapy is necessary.
Phase 2: Intensification or consolidation
Intensification or consolidation is continued treatment with chemotherapy to kill additional leukemia cells. This phase will include chemotherapy drugs given in the blood, in the vein, in the spinal fluid, and sometimes in the muscle. Radiation therapy also may be given to the brain during this phase.
Phase 3: Maintenance or continuation
The goal of this stage is to eradicate all leukemia from the body. Usually during this phase, less intensive chemotherapy is used, much of which can be given at home. This phase will last for many months. Your child must visit his physician regularly during this stage to determine response to treatment, detect any recurrent disease, and manage any side effects of treatment.
What is minimal residual disease (MRD)?
Minimal residual disease (MRD) is a term that is used for the “invisible” leukemia that is left behind after your child is in complete remission. It means that leukemia cells are still in your child's body, but there are too few of them to see them under a microscope.
Doctors use special tests after the end of the induction phase to measure the amount of MRD remaining in a patient's marrow.
The results of MRD tests are used to help determine the type of treatment your child’s doctor will recommend during the intensification phase of treatment. Children with higher levels of MRD at the end of induction are often given stronger chemotherapy drugs during the intensification phase to kill the remaining leukemia cells hiding in the body.
The prognosis for children with ALL is very positive. The five-year, event-free childhood acute lymphoblastic leukemia survival rate (which refers to survival without relapse) is about 85 percent. Ultimately, more than 90 percent of patients are cured of the disease.
The prognosis (chance of recovery) and treatment options depend on:
As with any cancer, prognosis and long-term survival can vary greatly. Relapse can occur during any stage of treatment, even with aggressive therapy, or may occur months or years after treatment has ended.
For patients with relapsed ALL, CAR
(chimeric antigen receptor) T-cell therapy is a promising new treatment. Dana-Farber/Boston Children's is a certified treatment center for providing this therapy. In general, relapsed ALL cells become resistant to chemotherapy drugs. CAR T-cell therapy instead utilizes genetic engineering of a patient's own T-cells to target and destroy cancer cells.
Prompt medical attention and aggressive therapy are important for the best prognosis, and continuous follow-up care is essential. New methods are continually being discovered to improve treatment and decrease side effects of the treatment for the disease.
Childhood cancer was once considered to always be fatal, but today, the majority of children diagnosed with cancer can expect to be long-term survivors.
Survivorship comes with numerous complex issues: the long-term effects of treatment and the risk of second cancers, as well as social and psychological concerns.
Since 1993, physicians, nurses, researchers, and psychologists in our cancer survivorship program at the David B. Perini, Jr. Quality of Life Clinic at Dana-Farber/Boston Children’s have helped thousands of survivors of pediatric cancers, treated at the institute and at other hospitals in New England and elsewhere, to manage these long-term consequences.
Phone: 617-632-5508Online form: Request an appointment
Andrew Place, MD, PhD, offers basic information about pediatric leukemia – including what to look out for.
World class cancer care at the #1 Children's Hospital
CAR (chimeric antigen receptor) T-cell therapy is a promising new treatment for some of the most challenging cases we face in pediatric acute lymphoblastic leukemia (ALL).